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Abstract
Background: CD81, a cell-surface protein of the tetraspanin superfamily, has been shown to
costimulate T cell activation in murine T cells, and is involved in development of Th2 immune
responses in mice.
Results: Here it is shown that stimulation of CD81 on human T cells can enhance T cell activation
by antigen or superantigen, causing an increase in the early activation marker CD69, and increasing
the number of cytokine-producing and proliferating T cells. Interestingly, CD81 costimulates
cytokine production by T cells producing both Th1 and Th2 cytokines. Although human CD81 is
highly expressed on non-T as well as T cells, CD81 costimulation appears to act directly on T cells.
Pre-incubation of purified T cells with anti-CD81 antibody is sufficient to increase T cell activation,
while pre-incubation of non-T cells is not. However, long-term polyclonal stimulation of T cells by
anti-CD3 antibody, in the presence of CD81 costimulation, biases T cells towards the production
of IL-4 and not IFNγ. This is accomplished by a preferential proliferation of IL-4-producing cells.
Conclusion: Thus, signalling through CD81 on T cells costimulates both Th1 and Th2 cells, but
increases the number of Th2 cells during long-term activation.
Background
The tetraspanins are a family of cell-surface proteins with
four transmembrane domains, two extracellular loops,
and conserved cysteine residues at key positions in the sec-
ond extracellular loop [1]. They facilitate a wide array of
functions, including cell activation, differentiation, adhe-
sion, morphological changes, and motility, which may all
relate to the promiscuous associations of these molecules
with integrins and other signaling proteins within the cell
membrane and the cytoskeleton.
CD81, a defining member of the tetraspanin superfamily,
is widely expressed on human hematopoietic and other
cells [2]. It associates on B cells with a signaling complex
that includes CD19 and CD21 [3], as well as associating
with MHC class II molecules [4] and other tetraspanins
[5,6]. On T cells, CD81 interacts with CD4, CD8, CD82,
and selected integrins [7–10].
An anti-CD81 antibody was first isolated for its ability to
induce cell death in B cell lines [11]. This is likely depend-
ent upon CD81's association with MHC class II mole-
cules, which can transmit death-inducing signals in B cells
[12]. CD81 cross-linking can also induce adhesion in B
and T cells, apparently by multiple pathways [10,13,14].
Triggering of the CD19-CD21-CD81 complex on murine
Published: 19 February 2003
BMC Immunology 2003, 4:1
Received: 20 September 2002
Accepted: 19 February 2003
This article is available from: http://www.biomedcentral.com/1471-2172/4/1
© 2003 Maecker; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media 
for any purpose, provided this notice is preserved along with the article's original URL.BMC Immunology 2003, 4 http://www.biomedcentral.com/1471-2172/4/1
Page 2 of 14
(page number not for citation purposes)
B cells has been shown to lower the threshold for B cell ac-
tivation via the immunoglobulin receptor [15].
On murine T cells and thymocytes, CD81 costimulates T
cell receptor-mediated activation, through a pathway in-
dependent of CD28 [16]. On human T cells, CD81 cos-
timulation results in increased IL-2 production and LFA-
1-mediated T-B cell adhesion [17]. Murine CD81 also ap-
pears to play a role in thymocyte maturation as shown in
fetal thymic organ cultures [18].
Finally, CD81 signalling has been shown to have an effect
on the Th1/Th2 balance of immune responses. In cell cul-
tures of CD4 T cells and B cells from allergic individuals,
addition of anti-CD81 antibody enhances IL-4 produc-
tion from the T cells [19]. In mice, either complete lack of
CD81, or lack of CD81 on B cells, leads to impaired hu-
moral and Th2 immune responses [20,21]. Allergen-in-
duced airway hyperresponsiveness is also decreased in
CD81null mice [22]. Finally, lack of CD81 on murine T
cells diminishes IL-4 production, with reduced expression
of ICOS, GATA-3, STAT6 and phosphorylated STAT6 [23].
In this report, an attempt is made to reconcile the findings
of general T cell costimulation versus specific Th2 biasing
by CD81 in human T cells. Short-term CD81 cross-linking
on normal human T cells is shown to co-stimulate T cell
activation (via antigen or superantigen), extending previ-
ous findings in mouse splenocytes [16] and human PBMC
[17]. The effect appears to be a direct consequence of
CD81 triggering on T cells. Of interest, production of both
Th1 and Th2 cytokines is augmented by CD81 costimula-
tion. However, during longer-term stimulation of T cells,
the presence of CD81 costimulation leads to a dispropor-
tionate increase in IL-4-producing cells. This is due to in-
creased induction of proliferation. Thus, CD81 signalling
provides short-term costimulation of cells producing Th1
or Th2 cytokines, but results in a disproportionate in-
crease in Th2 cytokine-producing cells during long-term
activation.
Results
CD81 cross-linking costimulates CD69 expression and IL-2 
induction
Two early events in T cell activation are the induction of
CD69 expression and the stimulation of IL-2 production
by the T cells. To determine whether costimulation
through human CD81 affected these early activation
events, peripheral blood cells from normal CMV seropos-
itive donors were incubated for 6 h with a superantigen,
SEB, or the viral antigen, CMV, in the presence or absence
of an agonistic anti-CD81 mAb, 5A6. As seen in Figure 1,
over a range of antigen or superantigen concentrations,
the addition of 5A6 increased the number of CD69+ cells
as well as the number of IL-2-producing cells, measured
by intracellular staining. The effect of anti-CD81 mAb was
often greater than that of the classical costimulatory anti-
body, CD28. The effect of anti-CD81 was also greater for
CD4+ T cells (A, B, E, F) compared to CD4- T cells (C, D,
G, H). It also appeared to be more dramatic for CD69
(A,C,E,G) than for IL-2 (B,D,F,H). As such, essentially no
effect was observed on CD8 (CD3+CD4-) T cell IL-2 pro-
duction (panels D and H). Stimulation with 5A6 alone, in
the absence of SEB or CMV, gave consistently = 0.05% cy-
tokine-positive T cells in such experiments (data not
shown). These results confirm and extend the findings of
VanCompernolle et al. [17] on CD81 costimulation of
SEB-induced CD69 expression.
Similar to results obtained by VanCompernolle et al. [17],
CD81 costimulation was also found to increase SEB-spe-
cific proliferation, as measured by BrdU incorporation
(data not shown).
Effect on Th1 and Th2 cytokines
Since CD81 signaling has been implicated in the mouse to
be preferentially important for Th2-dominated responses
[21], it was examined whether CD81 costimulation in hu-
man T cells preferentially induced Th2 cytokine produc-
tion over Th1 cytokine production. To examine this, 6 h
stimulation with SEB or CMV was carried out in peripher-
al blood cells of normal human CMV seropositive donors,
in the presence or absence of anti-CD81 mAb 5A6, fol-
lowed by intracellular staining for IL-2, IFNγ, or IL-4. As
seen in Figure 2, addition of 5A6 approximately doubled
the number of cytokine-producing cells for each cytokine
at these doses of SEB (0.1 µg/ml) or CMV (0.5 µg/ml).
There was no preferential costimulation of cells producing
IL-4 versus IFNγ or IL-2.
CD81 exerts a direct effect on human T cells
To determine whether the effects observed in the above
experiments were due to direct stimulation of CD81 on T
cells, or whether indirect effects of ligation of CD81 on
other cells were involved, the following experiment was
carried out. PBMC from a normal human donor were de-
pleted of non-T cells by magnetic bead separation, then T
cells and non-T cells were independently incubated with
5A6 anti-CD81 mAb, washed, and re-combined in the
presence of SEB. As seen in Figure 3, only when the T cell
fraction was incubated with 5A6 was costimulation of
CD69 expression and cytokine production observed.
Thus, direct ligation of CD81 on T cells was sufficient to
induce costimulation of T cell activation.
Effect of CD81 ligation on long-term T cell activation
Another possible way that CD81 could affect T cell cy-
tokine production is by directing T cells towards Th2
cytokine production during long-term stimulation. Other
investigators have shown (in mouse systems) thatBMC Immunology 2003, 4 http://www.biomedcentral.com/1471-2172/4/1
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Figure 1
Costimulatory effect of CD81 stimulation on CD69 expression (A, C, E, and G) and IL-2 production (B, D, F, 
and H), measured by cytokine flow cytometry. Whole blood from a CMV seropositive donor was stimulated for 6 h 
with varying concentrations of SEB (A-D) or CMV (E-H) in the presence of the activator alone (open circles), an irrelevant iso-
type control antibody (open squares), 5 µg/ml anti-CD28 mAb (closed circles), or 5 µg/ml 5A6 anti-CD81 mAb (closed 
squares). CD69 and IL-2 were then quantitated by intracellular staining on CD3+CD4+ cells (A, B, E, F) or CD3+CD4- cells (C, 
D, G, H). Results are representative of three experiments.
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Figure 2
Effect of CD81 stimulation on production of Th1 and Th2 cytokines. (A) Cytokine flow cytometry data from 0.1 µg/
ml SEB stimulation of whole blood in the absence (top panels) or presence (bottom panels) of 5 µg/ml 5A6 anti-CD81 mAb. 
(B) Similar experiment using 0.5 µg/ml CMV stimulation in the absence (top panels) or presence (bottom panels) of 5A6. Pro-
duction of all three cytokines was equally increased in the presence of CD81 costimulation. Results are representative of three 
experiments.
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commitment to Th1 or Th2 cytokine production by naïve
T cells requires prior cell proliferation [24]; and reversal of
Th1 or Th2-committed cells requires at least several days
of proliferation [25]. When normal human PBMC were
stimulated for 7 days with SEB, the presence of 5A6 anti-
CD81 mAb resulted in a modest increase in IL-4-produc-
ing T cells, when those cells were restimulated with PMA
and ionomycin (Figure 4A). No significant change in IL-2-
or IFNγ-producing T cells was seen. Similar results were
seen when PBMC were stimulated with plate-bound anti-
CD3 mAb, rather than SEB, for 7 days in the presence of
5A6 anti-CD81 mAb (Figure 4B). These results were more
dramatic when CD45RO+ cells were first isolated, by mag-
netic bead separation, and then subjected to 7 d stimula-
tion by anti-CD3, in the presence or absence of 5A6 anti-
CD81 mAb. As seen in Figure 4C, the percentage of CD4+
T cells producing IL-4 upon PMA+ionomycin restimula-
tion was increased more than 6-fold when 5A6 anti-CD81
mAb had been added to the initial anti-CD3 culture. No
significant change in IL-2 or IFNγ-producing cells was
seen. A less dramatic increase in IL-4-producing cells was
seen for CD45RO- cells (Figure 4D). The results for CD8+
T cells mirrored those for CD4+ T cells, except that the
overall number of IL-4-producing CD8+ T cells was lower
(data not shown).
Because the effect of CD81 on IL-4-producing T cells was
most dramatic with CD45RO+ cells (Figure 4C), it was
hypothesized that CD81 costimulation was affecting the
number of IL-4-producing memory T cells over time. To
determine the effect of CD81 costimulation over time on
the absolute number of IL-4- or IFNγ-producing T cells,
the experiment of Figure 5 was carried out. CD45RO+ T
cells were stimulated with anti-CD3 ± anti-CD81 mAb as
in Figure 4, but cells were restimulated with PMA + iono-
mycin after 1, 3, or 7 d of culture. The absolute number of
IL-4- and IFNγ-producing T cells was then quantified us-
ing intracellular staining and TruCount™ beads. As seen in
Figure 5, the number of IL-4-producing CD4 T cells in-
creased much more significantly over time in cultures in-
cubated with anti-CD81 mAb than in those without. The
number of IFNγ-producing CD4 T cells increased similarly
in cultures incubated with or without anti-CD81 mAb.
Thus, CD81 costimulation appeared to preferentially in-
duce the accumulation of IL-4-producing T cells over
time.
To further test whether CD81 costimulation was inducing
preferential proliferation of IL-4-producing memory cells,
experiments with CFSE labeling were carried out. As seen
in Figure 6A, the percentage of IL-4-producing cells in-
creased preferentially over time in long-term anti-CD3
stimulations that received CD81 costimulation, relative to
stimulations in the absence of anti-CD81 mAb. Although
CFSE content was equal in all cells on day 0 (Figure 6B),
the mean level of CFSE fluorescence of IL-4-producing
cells became lower over time in the presence of CD81 cos-
timulation versus anti-CD3 stimulation alone (Figure 6B
and 6C). This indicates that IL-4-producing cells had di-
vided, on average, more times with CD81 costimulation
than without. The difference was apparent after one day of
stimulation, and did not increase over time, consistent
with a greater initial induction of proliferation of IL-4-
producing cells in the presence of anti-CD81. There was
no such difference in CFSE levels for IFNγ-producing cells
in the presence or absence of anti-CD81 (Figure 6D).
However, anti-CD28 costimulation induced lower levels
of CFSE in all cells, including IFNγ-producing cells, after 3
days of anti-CD3 stimulation (p < 0.001, data not
shown). Thus, CD81 costimulation appears to uniquely
induce greater proliferation of IL-4-producing cells rela-
tive to other memory T cell populations.
Discussion
In this study, it was shown that CD81 ligation on human
T cells costimulates the induction of CD69 expression, the
production of cytokines, and the proliferation of both
CD4+ and CD4- human T cells. Greater effects were seen
on CD4+ T cells compared to CD4- T cells. The costimula-
tory effects were documented using two antigenic systems:
a superantigen (SEB), and a conventional viral antigen
Figure 3
CD81 costimulation occurs via direct action on T 
cells. PBMC were treated with magnetic beads for depletion 
of non-T cells, then T cells or non-T cells were treated for 
one hour on ice with 10 µg/ml 5A6 anti-CD81 mAb, washed 
twice, and re-mixed. The cultures were then stimulated for 6 
h in the presence of 0.1 µg/ml SEB, and CD69 and IL-2 
expression were quantitated by intracellular staining. Note 
that pre-treatment of T cells, but not non-T cells, resulted in 
augmentation of CD69 expression and IL-2 production. 
Error bars represent S.D. Results are representative of three 
experiments.
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(CMV). The effects were determined to be a direct conse-
quence of CD81 ligation on T cells, as anti-CD81 mAb
pre-treatment of purified T cells, but not non-T cells, in-
duced the costimulatory effects.
In a previous study, Van Compernolle et al. showed that
the enhancing effect of CD81 on SEB-induced activation
was inhibited by antibody to LFA-1 [17]. The current re-
sults are consistent with the model proposed by VanCom-
pernolle et al., whereby CD81 ligation induces an increase
in LFA-1 avidity for ICAM-3 on accessory cells, resulting in
an indirect activation effect on the T cells. However, in the
current study, anti-LFA-1 was found to only partially
block cytokine production induced by either SEB or
SEB+anti-CD81 (data not shown). This suggests that
CD81's effects on cytokine production may not be
uniquely mediated by LFA-1. In fact, other investigators
have shown that anti-CD81 mAb can directly costimulate
purified murine T cells [16], in a presumably LFA-1-inde-
pendent manner.
CD81 costimulation increased in equal proportion the
number of T cells producing IL-2, IFNγ, and IL-4. Using
CD81null  mice, CD81 was found to be required for
Figure 4
Long-term stimulation in the presence of 5A6 anti-CD81 mAb biases towards IL-4-producing T cells. (A and B) 
Unfractionated PBMC were cultured for 7 days with either 1 µg/ml SEB (A), or plate-bound anti-CD3 mAb (B) in the presence 
or absence of 5 µg/ml 5A6 anti-CD81 mAb (added once at the beginning of the culture period). After 7 days the cells were 
removed and restimulated for 4 h with PMA+ionomycin, and cytokine-producing T cells were enumerated by intracellular 
staining. (C and D) CD45RO+ cells (C) or CD45RO- cells (D) were isolated from PBMC by magnetic beads, then plated and 
stimulated for 7 days with plate-bound anti-CD3 as in panel (A). Cells were then removed and restimulated as above, and 
CD4+ or CD8+ T cell cytokine production measured by intracellular staining. Error bars represent S.D. Results are represent-
ative of four similar experiments.
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effective Th2, but not Th1, immune responses [20–23].
But CD81 has also been found to generally costimulate T
cell responses in mouse [16] and human [17]. Thus, the
costimulation of T cell cytokine production by CD81 need
not necessarily be biased towards Th2 cytokines. The cur-
rent results bear this out.
More recent results have shown that CD81 expression on
T cells is indeed important for their induction of IL-4 pro-
duction [23] in a mouse system. The current study com-
plements these results by demonstrating that CD81
directly influences the number of IL-4-producing T cells in
cultures of stimulated human memory T cells. The effect
of anti-CD81 mAb was to increase the absolute number of
IL-4-producing T cells over time relative to cultures not
costimulated with anti-CD81 mAb. Furthermore, the
CD81 costimulation appeared to cause a greater induc-
tion of proliferation of IL-4-producing cells, relative to
that seen in the absence of CD81 mAb.
The effect of CD81 costimulation on the number of IL-4-
producing T cells could occur through several different
mechanisms. First, it is possible that CD81 induces re-
cruitment of naïve cells to the Th2 pathway. This did not
appear to be the case, as the effect of CD81 was most
prominent on CD45RO+ cells, which do not include naïve
T cells. However, CD81 signalling could induce the
switching of some IFNγ-producing (Th1) T cells to IL-4-
producing (Th2) T cells over time. This is a difficult mech-
anism to test, due to the low number of IL-4-producing T
cells in human PBMC relative to IFNγ-producing T cells.
Experiments attempting to deplete IL-4-producing T cells
prior to anti-CD3 stimulation were attempted, but could
not be accurately interpreted, since depletion of 100% of
potential IL-4-producing cells could not be documented
(data not shown). It was thus impossible to rule out this
mechanism as possibly contributing to the accumulation
of IL-4-producing cells over time, although it did not ap-
pear to be the major mechanism (see below).
Second, it is possible that CD81 costimulation preferen-
tially rescues IL-4-producing T cells from apoptosis, and
thus they accumulate to a greater degree over time. This
did not appear to be the case, as IL-4-producing T cells
were no more likely to be apoptotic than IFNγ-producing
or IL-4-negative T cells in long-term stimulations (data
not shown).
Finally, it is possible that CD81 induces preferential pro-
liferation of IL-4-producing T cells relative to other T cells.
This indeed appears to be the case, as seen by proliferation
experiments using CFSE (see Figure 6). As cells divide, this
cytosolic dye is diluted, such that cells express lower levels
of CFSE with each successive division. Indeed, after just
one day of stimulation, IL-4-producing cells in the pres-
ence of CD81 costimulation had lower mean levels of
CFSE than did IL-4-producing cells in the absence of
CD81 costimulation. This was not true for IL-4-negative
or IFNγ-producing cells. The relative amount of CFSE in
CD81-costimulated cultures versus non-costimulated cul-
tures did not change further over time. Thus, it did not ap-
pear that IL-4-producing cells were continually
proliferating faster in the presence of CD81 costimula-
tion. Rather, they appeared to be more readily induced
into proliferation, as the maximum difference in CFSE lev-
els was already observed after one day of stimulation.
Thus, the primary mechanism by which CD81
costimulation induces Th2 bias in long-term stimulation
appears to be a greater induction of proliferation in IL-4-
producing cells. This complements the findings of Deng et
al. [23], in which the lack of CD81 in a murine culture sys-
tem correlated with decreased expression of signalling
molecules critical for activation and IL-4 production. This
effect of CD81 is not shared by other classical costimula-
tory molecules, such as CD28, which has been shown to
induce the proliferation of both Th1 and Th2 cells (data
not shown, and references [26–29]).
Figure 5
CD81 costimulation results in the accumulation of 
IL-4-producing CD4 T cells over time. CD45RO+ cells 
were stimulated with plate-bound anti-CD3 mAb in the pres-
ence or absence of 10 µg/ml 5A6 anti-CD81 mAb for 1, 3, or 
7 days. They were then restimulated for 4 h with PMA+iono-
mycin, and cytokine-producing T cells were enumerated by 
intracellular staining. (A) The absolute number of IL-4-pro-
ducing CD4 T cells increases more dramatically over time in 
the presence of anti-CD81 mAb than in its absence. (B) The 
absolute number of IFNγ-producing CD4 T cells is similar 
over time in cultures incubated with or without anti-CD81 
mAb. Error bars represent S.D. Results are representative of 
two similar experiments.
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Figure 6
CD81 costimulation induces preferential proliferation of IL-4-producing cells. CD45RO+ PBMC were labeled with 
CFSE as described in Materials and Methods. They were then stimulated with plate-bound anti-CD3 mAb in the presence or 
absence of 5 µg/ml 5A6 anti-CD81 mAb for 1, 4, or 7 days. At these time points, cells were restimulated for 4 h with 
PMA+ionomycin, and cytokine-producing T cells were enumerated by intracellular staining. (A) The percentage of IL-4-produc-
ing cells increased faster over time in anti-CD81 mAb-treated cultures. (B) CFSE content of all cells at day 0 (left panel) was 
equal in the presence of anti-CD81 mAb (solid histogram) or in its absence (dotted histogram). The CFSE content of IL-4-pro-
ducing cells (right panel) was lower in the presence of anti-CD81 mAb (solid histogram) than in its absence (dotted histogram), 
after 4 days of stimulation. (C) The mean CFSE content of IL-4-producing cells was lower in the presence of anti-CD81 mAb 
than in its absence (left panel); there was no such difference for IL-4-negative cells (right panel). (D) The mean CFSE content of 
IFNγ-producing or IFNγ-negative cells did not differ in the presence or absence of anti-CD81 mAb. Thus, CD81 costimulation 
preferentially induces proliferation of IL-4-producing cells. Results are representative of two similar experiments.
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It should be noted that the present study, due to limita-
tions of working with human PBMC, could not address
the results of withdrawing endogenous CD81 signalling.
Rather, CD81 co-stimulation could only be increased over
basal levels by application of an agonistic mAb, 5A6. Be-
cause endogenous CD81 costimulation could still occur
in cultures without 5A6 added, the differences due to ad-
dition of 5A6 might actually underestimate the full poten-
tial of CD81's effect. This caveat of the experimental
system also implies that there could be considerable do-
nor-to-donor variability in the effect of anti-CD81 mAb,
as different donors could have different levels of endog-
enous CD81 costimulatory activity. The natural ligand for
CD81 has never been identified.
Conclusions
In conclusion, CD81 costimulation appears to have mul-
tiple effects on T cells, including costimulation of Th1 and
Th2 cytokine production in short-term assays, and prefer-
ential induction of Th2 cell proliferation in long-term cul-
tures of human memory T cells. These results expand
upon and help to explain the Th2-biasing effects of CD81
in mouse [21–23] and human [19] systems.
Methods
Cells and cell separation
Peripheral blood from normal human donors was collect-
ed under informed consent in accordance with an institu-
tionally-approved and physician-supervised protocol.
Blood was collected in heparinized Vacutainer™ tubes or
heparinized CPT tubes (BD Vacutainer, Franklin Lakes,
NJ). CPT tubes were centrifuged as directed by the manu-
facturer to obtain peripheral blood mononuclear cells
(PBMC). These were resuspended for stimulation in the
autologous plasma. For the experiments of Figures
3,4,5,6, PBMC were further fractionated using magnetic
beads (Milltenyi Biotec, Auburn, CA) to deplete non-T
cells, and/or to select for CD45RO+ versus CD45RO- cells.
Cell separation was performed on an AutoMACS system
(Milltenyi) according to the manufacturer's instructions.
For Figure 4, separated cells were then aliquoted and treat-
ed (or not) with 5 µg/ml 5A6 anti-CD81 mAb ([11], a gift
of Shoshana Levy, Stanford University) for one hour on
ice. Cells were then washed twice with medium, and
resuspended in 0.5 ml medium. T cells (treated or not)
were recombined with non-T cells (treated or not) for
stimulation with SEB as described below. Medium con-
sisted of RPMI-1640 + 10% fetal bovine serum and
antibiotics.
Antigens
Human cytomegalovirus (CMV) lysate was obtained from
Advanced Biotechnologies (Columbia, MD), aliquoted
and stored at -80°C, and used at the doses indicated in the
figures. Staphlococcal enterotoxin B (SEB), a superanti-
gen, was obtained from Sigma Chemical Co. (St. Louis,
MO), and used at the doses indicated in the figures.
Short-term stimulations
0.2–1 ml of whole blood or PBMC was stimulated in 15
ml conical polypropylene tubes (Falcon, BD Discovery La-
bware, Bedford, MA) or 2 ml microtubes (Sorenson Bio-
Science, Salt Lake City, UT). For experiments examining
cytokine production and CD69 induction, whole blood
or PBMC were incubated with antigen or superantigen for
6 h at 37°C, with addition of 10 µg/ml Brefeldin A (Sig-
ma) at 2 h. For experiments examining proliferation,
PBMC were incubated with SEB for 48 h at 37°C, with ad-
dition of 60 µM BrdU (Sigma) and 10 µg/ml Brefeldin A
for the last 6 h. Whole blood was incubated in upright
tubes, while PBMC were incubated in tubes slanted to 5°
above horizontal. Incubations were carried out in the
presence or absence of 5 µg/ml purified 5A6 anti-human
CD81 mAb.
Long-term stimulations
For stimulation with anti-CD3 mAb, 24-well or 6-well tis-
sue culture plates (Falcon) were coated with purified anti-
CD3 mAb (clone JE6 [30]). A 10 µg/ml solution of JE6 in
PBS was added to each well and incubated for 2 h at 37°C.
Wells were then washed several times with PBS prior to
addition of cells. PBMC, or fractions of PBMC isolated by
magnetic bead separation, were resuspended in RPMI me-
dium + 10% fetal bovine serum (Sigma), supplemented
with L-glutamine and antibiotics, and plated at
approximately 106 cells per ml. The cells were stimulated
either with plate-bound anti-CD3 mAb (coated as de-
scribed above) or soluble SEB superantigen (Sigma, at 1
µg/ml final concentration), in the presence or absence of
5–10 µg/ml 5A6 anti-CD81 mAb (added only at the initi-
ation of the culture). After 1–7 days, cells were stimulated
for 4 h with 10 ng/ml PMA + 1 µg/ml ionomycin (both
from Sigma), in the presence of 10 µg/ml Brefeldin A.
Cell preparation and staining
Cells were prepared for cytokine flow cytometry as de-
scribed previously [31–33]. Briefly, cells were incubated
15 min with 2 mM EDTA to remove adherent cells, then
treated with 10 volumes of FACS Lysing Solution (BD Bi-
osciences, Immunocytometry Systems, San Jose, CA) for
10 min at room temperature. Cells were washed, aliquot-
ed into 12 × 75 mm polystyrene tubes (Falcon), and treat-
ed with 0.5 ml FACS Permeabilizing Solution 2 (BD
Immunocytometry Systems) for 10 min at room tempera-
ture. After washing once more, cells were stained (30–60
min at room temperature) for flow cytometry, typically
with anti-cytokine FITC/CD69 PE/CD4 PerCP-Cy5.5/
CD3 APC. For proliferation experiments, cells were
stained with anti-BrdU FITC/anti-cytokine PE/CD4 PerCP
(all antibodies from BD Immunocytometry Systems).BMC Immunology 2003, 4 http://www.biomedcentral.com/1471-2172/4/1
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After an additional wash, cells were fixed with 1% parafor-
maldehyde for flow cytometry analysis.
Flow cytometry
Samples were collected on a FACSCalibur flow cytometer
using CellQuest software (BD Immunocytometry Sys-
tems). In general, 20,000–100,000 CD3-gated (or, in
some experiments, CD4-gated) lymphcytes were ac-
quired, using a logical gate on forward versus side scatter
and CD3 (or CD4) versus side scatter. For experiments ex-
amining cytokine production and CD69 induction, a "re-
sponse region" was defined for CD69+cytokine+  cells
using a positive control such as SEB stimulation, on a
CD4-gated dot plot. Background responses in the pres-
ence of 5A6 anti-CD81 antibody alone were less than
0.05% in all experiments shown.
Absolute cell counts
Absolute numbers of CD4+ T cells producing IL-4 or IFNγ
were calculated by spiking samples, processed and stained
as above, with 10 µl of TruCount™ High control beads
(BD Immunocytometry Systems). Samples were then ac-
quired with a threshold on FL4 (CD3), rather than for-
ward scatter, and the number of beads per sample were
calculated by gating on the bead population in a forward
versus side scatter dot plot. The number of cytokine-pro-
ducing cells per ml were then calculated as: [(number of
gated cells)/(number of gated beads)] × [number of beads
per sample].
CFSE labeling
PBMC magnetically enriched for CD45RO+ cells were la-
beled with 5(6)-carboxyfluorescein diacetate, succinimi-
dyl ester (CFSE, Sigma) as follows. A 0.5 mM stock
solution of CFSE in DMSO was aliquoted and stored at -
20°C. Just prior to use, an aliquot was thawed and 2 µl of
stock solution were diluted into 10 ml of PBS. CD45RO+
cells were washed once in PBS and resuspended in 1 ml of
the CFSE/PBS solution. After incubating 2 min at room
temperature, the cells were washed once with 10 ml of
RPMI medium + 10% fetal bovine serum (supplemented
with L-glutamine and antibiotics). They were then plated
in wells of a 24-well plate as under "Long term stimula-
tions" above.
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